Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
|Articles|March 24, 2023
5 Key Sessions, Interviews at 2023 APhA Annual Meeting & Exposition
Author(s)Erin Hunter, Assistant Editor
Pharmacy Times is covering the American Pharmacists Association (APhA) Annual Meeting & Exposition in Phoenix, Arizona from March 24 to 27, 2023.
Advertisement
The theme of this year’s APhA meeting is “Rise! Advancing in the Face of Adversity.” The gathering will provide pharmacy professionals with the opportunity to learn about innovations in the industry, connect with other pharmacists, and work together to tackle obstacles with ingenuity and creativity.
Stay tuned on PharmacyTimes.com for exclusive session coverage and interviews with experts, including:
- Michael D. Hogue, PharmD, FAPhA, FNAP, FFIP, dean and professor at Loma Linda University School of Pharmacy, who will provide an update on the 2023 immunization recommendations and offer insight about the status of COVID-19 vaccines.
- Coverage of a session on pain management that delves into alternative, non-pharmacologic interventions to treat chronic pain and develop appropriate treatment strategies.
- A discussion with Kathryn Marwitz, PharmD, MPH, who will dive into debunking misinformation in the pharmacist’s workplace. She will explore social media, the repercussions of patient wellbeing because of misinformation, and how to help facilitate communication of truthful scientific information.
- Coverage of a session on adult ADHD which will delve into how ADHD affects adult patients, and how pharmacists can create a plan to help patients manage the condition.
- A conversation with Vibhuti Arya, PharmD, MPH, FAPhA, who will discuss drug decriminalization, it’s impact on public health, and how pharmacy professionals can address its stigma with patients.
Stay tuned on
Advertisement
Related to this article
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Pharmacy Times previews enlicitide, survodutide, diet and heart failure risk, and pharmacist-led HF care ahead of the AHA Scientific Sessions in Chicago.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
3
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
4
Lilly–Hims & Hers GLP-1 Deal Tests Whether Convenience Can Deliver Continuity of Care
5